|
|
|
| |
Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms ( ), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.
|
|
|
|
|
|
|
The potent hemostatic effects of TT-103MH have also been observed in samples from patients with congenital platelet disorders, such as the Bernard-Soulier Syndrome and Glanzmann's Disease. Thrombotargets is developing the first antihemorrhagic drug useful for treating topically all kinds of bleeding. Know more about us.
We have developed High Throughput Screening Pathway Activity named BioplatformScreen TM. A new High Through Screening Phatway Activity (HTS-PA) family raise, HemostaBioplatformScreen, OxidantBioplatformScree and AtheroBioplatformScreen.
The potent hemostatic effects of TT-103MH have also been observed in samples from patients with congenital platelet disorders, such as the Bernard-Soulier Syndrome and Glanzmann's Disease. Thrombotargets is developing the first antihemorrhagic drug useful for treating topically all kinds of bleeding. Know more about us.
|
|
|
|
